entertainment -WSS

entertainment

author：fashion 2025-09-29 17:02:25 - browse：194

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article：一旦重新出现在媒体曝光之下，多数都是以失败或相当负面的形象亮相。

entertainment

WSS

He's 19 months old and has one of the world’s rarest diseases

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

First over

Readout Newsletter: BridgeBio, Akero, and human embryo models

NIH fellows want a pay raise. Will that mean less money for grants?

Stem cell biologist probes earliest stages of human development

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Affirmative action in medical school literally saved lives

Living with Fabry disease, a condition that causes chronic pain

As demand for Covid shots wanes, Moderna seeks its next success

Biden launches a new push to limit health care costs

Hollywood unions extend contract negotiations for actors

Harvard's David Sinclair gets blowback over aging

ChatGPT in medicine: STAT answers readers' burning questions

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

United colonoscopy coverage change 'may cost lives,' doctors say

It's time to get medical device identifiers over the finish line

Wikipedia

The public health thinking behind the CDC’s new Covid guidance

New research casts further doubt on a common procedure used with IVF

Streamlined flu vaccines recommended by FDA advisory panel

The untold story of TV’s first prescription drug ad

N.Y. state detects polio case, first in the U.S. since 2013

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

hotspot

focus

entertainment

focus